DGAP-News: Biosilu Healthcare AG / Key word(s): Agreement
18.09.2017 / 12:18
Biosilu Healthcare AG (Frankfurt) and Glycotope GmbH (Berlin) signed term sheet for the development and commercialization of FSH-GEX(R) (follitropin epsilon) for China.
Frankfurt, September 18, 2017 – The life science company Biosilu Healthcare AG (ISIN DE000A0SMU87), listed on the Munich Stock Exchange, announced today the signing of a term sheet defining the framework of a future license and collaboration agreement between Biosilu Healthcare and Glycotope, a biopharmaceutical company based in Berlin. The framework agreement comprises China including Hong Kong and Macau. Financial details have not been disclosed.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Biosilu Healthcare AG|
|60313 Frankfurt am MAin|
|Phone:||+49 69 34 87 52 25|
|Listed:||Regulated Unofficial Market in Munich|
|End of News||DGAP News Service|
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.
Northern Data reports on course of business for July 2022 and expected total cryptocurrency production in 2022
Preliminary reported EBITDA EUR 50 million higher than reported on 30 June 2022. Northern Data expects finalization of audit 2021 financial statements in August 2022.
Get regular updates